Vasopressors & Inotropes: A Molecular Architecture

Why start at the receptor

You have almost certainly memorized a table like this: norepinephrine — alpha and some beta-1; phenylephrine — pure alpha; dobutamine — beta-1 with some beta-2. It gets you through orientation. It does not get you through the patient in front of you at 0300 who is on 40 mcg/min of norepinephrine with a MAP of 58, a lactate of 6, and a heart rate of 145.

The reason is that the table describes labels, not mechanisms. It cannot tell you why adding vasopressin at that moment often buys you 15 mcg/min of norepinephrine back, why the patient's arrhythmia burden went up before their pressure did, why a profoundly acidotic patient stops responding to the drug at all, or why the intensivist reaches for hydrocortisone.

All of those answers live one level down, at the receptor and the second messenger. And that layer is stable. Guidelines change every few years; the fact that norepinephrine binding to an α₁ receptor activates G_q, which activates phospholipase C, which liberates IP₃, which opens a calcium channel on the sarcoplasmic reticulum, has not changed and will not.

The shape of the module

We build in one direction only, from small to large:

1. The receptor. What a G-protein coupled receptor is and what the three relevant G proteins (G_q, G_s, G_i) do when they are switched on.
2. The two core pathways. The α₁/G_q route to vasoconstriction, and the β/G_s route to inotropy and chronotropy.
3. The non-catecholamine systems. Vasopressin at V₁, angiotensin II at AT₁, and the K_ATP channel that explains why vasodilatory shock becomes catecholamine-resistant.
4. The agents. Each drug as a profile of affinities rather than a memorized effect.
5. The strategy. Sequencing, catecholamine-sparing, SCAI shock stages, and what to do when nothing works.
6. The nursing actions the CCRN exam actually asks about — titration, extravasation, line selection, monitoring, and evaluating whether the intervention worked.

A note on numbers

Dose ranges and thresholds in this module are quoted from the source document that publishes them and are labeled as such. Institutions differ — some units cap norepinephrine at 30 mcg/min and add a second agent, others titrate to 100. Weight-based versus non-weight-based ordering (mcg/kg/min versus mcg/min) differs by hospital and is a real medication-safety hazard when nurses float between units. The mechanism is universal; the number on your pump is local. Always verify against your own protocol.

The G-protein coupled receptor: one machine, many outcomes

Nearly every drug in this module works through the same piece of cellular machinery: a G-protein coupled receptor, or GPCR. Adrenergic receptors (α₁, α₂, β₁, β₂), vasopressin receptors (V₁, V₂), angiotensin receptors (AT₁) and dopamine receptors are all GPCRs.¹

The anatomy of the switch

A GPCR is a single protein that threads back and forth through the cell membrane seven times — hence "seven-transmembrane receptor." The loops on the outside form the pocket where the ligand (norepinephrine, vasopressin, angiotensin II) binds. The loops on the inside touch a heterotrimeric G protein: three subunits called α, β and γ.

At rest, the α subunit holds a molecule of GDP and the trio sits together, inactive, tethered to the inner face of the membrane.

When a ligand binds the outside pocket, the receptor changes shape. That conformational change acts on the G protein like a lever: the α subunit releases GDP and picks up GTP instead. GTP-bound α separates from βγ, and both halves go off to do work on downstream effector enzymes. The α subunit slowly hydrolyzes its own GTP back to GDP, reassembles with βγ, and the switch turns itself off.

Which α subunit you get determines everything

The receptor's identity is essentially the identity of the G protein it is wired to. There are three that matter here:

Read that table twice. It is the whole module in miniature.

• Anything that ends in G_q is a vasoconstrictor — it squeezes vascular smooth muscle. Norepinephrine at α₁, vasopressin at V₁, angiotensin II at AT₁ all converge on the same intracellular endpoint by three independent front doors. That convergence is the entire rationale for multimodal vasopressor therapy.
• Anything that ends in G_s is an inotrope/chronotrope — it makes the heart squeeze harder and faster, and in vascular smooth muscle (β₂) it paradoxically causes relaxation, which is why epinephrine at low doses can drop your diastolic pressure.
• G_i is the brake. α₂ agonists like dexmedetomidine and clonidine reduce sympathetic outflow by activating it presynaptically.

Receptor location predicts side effect

Because receptors are distributed unevenly, you can predict adverse effects from anatomy alone:

• α₁: arterioles everywhere, but densest in skin, splanchnic bed and kidney. Hence pallor, cool extremities, mesenteric ischemia and oliguria at high doses. Also on the bladder neck and pupil dilator.
• β₁: predominantly cardiac — SA node, AV node, atrial and ventricular myocytes — plus juxtaglomerular cells (renin release). Hence tachycardia, arrhythmia, and increased myocardial oxygen demand.
• β₂: bronchial smooth muscle, skeletal-muscle arterioles, uterus, liver, and the Na⁺/K⁺-ATPase in skeletal muscle. Hence bronchodilation, decreased SVR, tremor, hyperglycemia (glycogenolysis) and hypokalemia — the last one matters when you start an epinephrine drip on a patient with an already-borderline potassium.
• V₁: vascular smooth muscle, with relatively preserved effect in acidosis and relatively less pulmonary vasoconstriction than catecholamines.
• AT₁: vascular smooth muscle, adrenal cortex (aldosterone), kidney.

α₁ activation: Gq, IP₃, calcium and the crossbridge

This is the pathway that raises a mean arterial pressure. Learn it as a chain of nine physical events, each one causing the next.

The chain

1. Ligand binds. Norepinephrine (or phenylephrine, or endogenous epinephrine) occupies the α₁ receptor on a vascular smooth muscle cell.
2. G_q is activated. The receptor changes shape; the G_qα subunit swaps GDP for GTP and dissociates from βγ.
3. Phospholipase C is switched on. G_qα-GTP binds and activates PLC-β, which sits on the inner leaflet of the membrane.
4. PIP₂ is cleaved. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP₂), a membrane lipid, into two fragments: IP₃ (inositol trisphosphate, water-soluble, diffuses into the cytosol) and DAG (diacylglycerol, lipid-soluble, stays in the membrane).^1,2
5. IP₃ opens the SR. IP₃ diffuses to the sarcoplasmic reticulum and binds the IP₃ receptor, a calcium release channel. Stored Ca²⁺ floods into the cytosol. Cytosolic calcium rises from roughly 100 nmol/L to the micromolar range.
6. More calcium arrives from outside. Depolarization and store depletion recruit voltage-gated and store-operated Ca²⁺ channels in the plasma membrane, sustaining the rise.
7. Calcium binds calmodulin. Four Ca²⁺ ions bind the small regulatory protein calmodulin, changing its shape.
8. MLCK is activated. The Ca²⁺–calmodulin complex binds and activates myosin light chain kinase.
9. The crossbridge forms. MLCK phosphorylates serine-19 on the regulatory myosin light chain. Phosphorylated myosin can now bind actin, cycle crossbridges, and shorten the cell.²

Multiply that by every smooth muscle cell in the arteriolar wall and the vessel narrows. Narrow enough vessels and systemic vascular resistance rises. MAP ≈ CO × SVR, so the pressure goes up.

Relaxation is not passive

When the ligand leaves, three things must happen for the vessel to relax: calcium is pumped back into the SR (by SERCA) and out of the cell (by the plasma-membrane Ca²⁺-ATPase and Na⁺/Ca²⁺ exchanger); calmodulin releases MLCK; and MLCP dephosphorylates myosin. All three are ATP-dependent to some degree.

Where α₁ constriction hurts

The arteriolar bed is not uniform. α₁ receptor density is high in skin, splanchnic circulation and renal cortex, and lower in the coronary and cerebral circulations (which are largely locally autoregulated). That distribution produces the classic high-dose picture: mottled cool extremities, rising creatinine, ileus and, at the extreme, mesenteric ischemia — while the brain and heart remain relatively perfused. It is a survival design, and it is also the reason a pressor-dependent patient can look adequately perfused on the monitor and be starving their gut.

Venous α₁: the forgotten half

Veins have α₁ receptors too. Constricting the venous capacitance bed shifts blood from the unstressed to the stressed volume — effectively an autotransfusion that raises venous return and preload. This is a real and underappreciated part of how norepinephrine works: some of its benefit comes from increased cardiac output via improved preload, not only from increased SVR.

β₁ and β₂: Gs, cAMP, PKA and the calcium transient

If α₁ is about squeezing the pipes, β is about the pump — and about one very specific molecule, cyclic AMP.

The β₁ chain in the cardiac myocyte

1. Ligand binds β₁ (norepinephrine, epinephrine, dobutamine, isoproterenol).
2. G_s activates adenylate cyclase, a membrane enzyme.
3. Adenylate cyclase converts ATP → cAMP. Cytosolic cAMP rises.
4. cAMP activates protein kinase A (PKA) by binding its regulatory subunits and freeing the catalytic ones.
5. PKA phosphorylates four critical targets:
   • L-type calcium channels (Ca_V1.2) in the sarcolemma and T-tubules → they open more readily and stay open longer → more Ca²⁺ enters on each action potential.
   • Ryanodine receptors (RyR2) on the sarcoplasmic reticulum → more calcium-induced calcium release for a given trigger.⁶
   • Phospholamban → phosphorylated phospholamban stops inhibiting SERCA2a, so the SR pump reloads calcium faster.
   • Troponin I → reduces myofilament calcium affinity, so calcium unbinds faster at the end of systole.
6. Net result: a bigger, faster calcium transient that also terminates faster.

That last part is the elegant bit. Targets 1–2 produce inotropy (a stronger contraction). Targets 3–4 produce lusitropy (faster relaxation), which is what allows the ventricle to still fill adequately at a heart rate of 130. Without lusitropy, tachycardia would be self-defeating.

Chronotropy is the same mechanism in the SA node

In SA nodal cells there is no stable resting potential — the "funny current" (I_f, carried by HCN channels) slowly depolarizes the cell to threshold. cAMP binds HCN channels directly, steepening phase 4 and reaching threshold sooner. That is the entire mechanism of β-agonist tachycardia. PKA also speeds AV nodal conduction (dromotropy) by phosphorylating its calcium channels.

β₂ in vascular smooth muscle: the same cAMP, the opposite result

Here is the part that trips people up. In vascular smooth muscle, cAMP causes relaxation:

• PKA phosphorylates and inactivates MLCK — the accelerator is disabled.
• PKA promotes calcium re-uptake into the SR and opens potassium channels, hyperpolarizing the cell and closing voltage-gated calcium channels.
• Net: less phosphorylated myosin, less crossbridge cycling, vasodilation.

So a drug with meaningful β₂ activity lowers SVR. This is why:

• Epinephrine at low doses can drop the diastolic pressure (β₂ vasodilation in skeletal muscle) even while raising cardiac output — the classic "low-dose epi widens the pulse pressure" finding.
• Dobutamine is an inodilator: it improves contractility while reducing afterload, which raises stroke volume nicely but can drop MAP in someone who has no reserve.
• Norepinephrine's weak β₂ activity is precisely why it is a better pure pressor than epinephrine — the vasodilating counterweight is small.

Other β₂ consequences you will chart

Receptor desensitization: why the drug stops working

Sustained agonist exposure triggers GRK-mediated phosphorylation of the receptor, β-arrestin binding, uncoupling from G_s, and eventually internalization and downregulation of receptor number. Clinically: escalating requirements over 24–48 hours despite an unchanged clinical picture, and the loss of effect that partly motivates adding a different receptor system rather than simply more of the same drug.⁸

Beyond catecholamines: V₁, AT₁ and the KATP channel

Catecholamines are one front door to G_q. There are two others, and understanding them is what makes modern multimodal vasopressor strategy make sense rather than feel like polypharmacy.

Why vasodilatory shock resists catecholamines

Late vasodilatory shock — septic, post-cardiopulmonary-bypass, post-arrest, hepatic — is not simply "not enough norepinephrine." Three mechanisms actively oppose you:^4,9

1. K_ATP channel activation. Falling cellular ATP and rising lactate/H⁺ open ATP-sensitive potassium channels in vascular smooth muscle. Potassium leaves, the cell hyperpolarizes, and voltage-gated calcium channels close. No calcium entry, no contraction — no matter how much α₁ agonist you supply.
2. Nitric oxide excess. Inflammatory cytokines induce iNOS; NO activates guanylate cyclase, cGMP rises, and cGMP-dependent kinase drives relaxation, calcium sequestration and MLCP activation. This is the same pathway nitroglycerin uses — the patient is, in effect, on an endogenous nitroglycerin infusion.
3. Relative vasopressin deficiency. Endogenous vasopressin stores in the posterior pituitary are depleted within hours of shock onset. Plasma levels that should be high are inappropriately normal or low.

Add acidosis, which reduces adrenergic receptor affinity, and critical illness–related corticosteroid insufficiency, which reduces receptor expression, and you have a cell that is close to unresponsive to catecholamines.

Vasopressin at V₁

Arginine vasopressin (ADH) is a nine-amino-acid peptide from the posterior pituitary. It has three receptors that matter:

Three properties make V₁ agonism useful in shock:

• It bypasses adrenergic receptors entirely, so adrenergic desensitization and acidosis don't blunt it as much.
• It closes K_ATP channels and blunts NO-mediated cGMP signaling, directly antagonizing two of the three vasoplegia mechanisms above.
• Preferential efferent arteriolar constriction in the glomerulus tends to preserve or raise glomerular filtration pressure — the physiologic rationale behind the renal signals seen in VASST and VANISH.^10,11

Vasopressin is given at a fixed, non-titrated dose — typically 0.03 units/min in septic shock (the VASST dose), sometimes up to 0.04 — because the dose–response is steep and higher doses cause digital, mesenteric and coronary ischemia without further benefit.^10,5

Angiotensin II at AT₁

Angiotensin II is the effector of the renin–angiotensin–aldosterone system, and synthetic angiotensin II is a third, independent G_q route.

The RAAS chain: renin (from juxtaglomerular cells, released in response to low renal perfusion, low distal sodium, and β₁ stimulation) cleaves angiotensinogen to angiotensin I; ACE — mostly in pulmonary endothelium — converts it to angiotensin II, which acts on AT₁ receptors to constrict vessels, release aldosterone, and promote sodium and water retention.

In shock this axis is often broken: pulmonary endothelial injury impairs ACE activity, so patients can have high angiotensin I with inadequate angiotensin II — a substrate deficiency you can bypass by giving the product directly.

Methylene blue and hydroxocobalamin: attacking the NO arm

Neither is a G_q agonist. Both work by suppressing the nitric oxide–cGMP pathway: methylene blue inhibits guanylate cyclase (and iNOS), hydroxocobalamin scavenges NO directly. They are used as rescue in refractory vasoplegia, most often post-cardiopulmonary bypass.⁹ Evidence is limited to small trials and case series; know them as concepts, and know that methylene blue causes transient blue-green urine and interferes with pulse oximetry, and is avoided in serotonergic patients (it is an MAO-A inhibitor) and in G6PD deficiency.

Corticosteroids: permissive, not pressor

Hydrocortisone is not a vasoconstrictor. It restores the responsiveness of the receptors you already have, upregulating adrenergic receptor expression and blunting inflammatory NO production. The Surviving Sepsis Campaign suggests IV corticosteroids for adults with septic shock and an ongoing vasopressor requirement — the typical trigger being norepinephrine or epinephrine ≥0.25 mcg/kg/min at least 4 hours after initiation, at 200 mg/day of hydrocortisone (50 mg q6h or a continuous infusion).^5,13

The agents, one by one

Each agent below is presented as an affinity profile first. If you know the profile, you can derive the hemodynamics, the side effects and the failure modes without memorizing them.

Norepinephrine (Levophed)

Profile: α₁ ≫ β₁ > β₂ (minimal). Typical range: 0.01–0.5 mcg/kg/min, or roughly 2–40 mcg/min in non-weight-based units; higher in refractory shock.

Strong α₁ constriction with enough β₁ to maintain — sometimes increase — cardiac output, and almost no β₂ to counteract the pressure rise. Venoconstriction adds preload. This combination is why it is first-line for septic shock and most vasodilatory shock, and increasingly first-line in cardiogenic shock.^5,16

Predictable problems: reflex bradycardia (baroreceptor response to the rise in MAP), digital and mesenteric ischemia at high dose, and tissue necrosis on extravasation.

Epinephrine

Profile: dose-dependent. At low doses β₁ ≈ β₂ > α₁; at higher doses α₁ dominates. Typical range: 0.01–0.5 mcg/kg/min for shock; 1 mg IV push q3–5 min in cardiac arrest; 0.3–0.5 mg IM for anaphylaxis.

Low-dose epinephrine raises cardiac output and can lower diastolic pressure through β₂ vasodilation; higher doses recruit α₁ and raise SVR. It is the first-line drug in anaphylaxis (β₂ bronchodilation + α₁ constriction + mast cell stabilization) and the third-line addition in septic shock when MAP is inadequate on norepinephrine plus vasopressin.⁵

Predictable problems: tachyarrhythmias, hyperglycemia, hypokalemia, and the β₂-driven lactate rise that can be mistaken for worsening perfusion.⁸

Phenylephrine

Profile: pure α₁. No β activity at all. Typical range: 0.5–9 mcg/kg/min infusion; 50–200 mcg IV push.

Pure vasoconstriction with reflex bradycardia and no direct inotropy. Cardiac output usually falls as afterload rises. Its niches are narrow but real: procedural/anesthetic hypotension, hypotension where tachyarrhythmia is the limiting problem, and hypertrophic obstructive cardiomyopathy or aortic stenosis, where increasing SVR without increasing contractility or rate is exactly what you want.

Not recommended as first-line in septic shock.⁵

Vasopressin

Profile: V₁ agonist; no adrenergic activity. Typical dose: 0.03 units/min fixed (up to 0.04) — not titrated.

An adjunct, added to norepinephrine to raise MAP and spare catecholamine dose.^5,10 Retains effect in acidosis. Watch for digital and mesenteric ischemia; it is generally stopped last or second-to-last during weaning in many protocols, though evidence on wean order is limited and practice varies.

Angiotensin II (Giapreza)

Profile: AT₁ agonist. Typical range: started at 20 ng/kg/min, titrated; maintenance often ≤40 ng/kg/min.

Rescue for catecholamine-refractory vasodilatory shock.¹² Requires VTE prophylaxis given the thrombosis signal in ATHOS-3.

Dopamine

Profile: dose-dependent — D₁ (low) → β₁ (moderate) → α₁ (high). The "renal dose" concept has been abandoned; low-dose dopamine does not protect kidneys. Typical range: 2–20 mcg/kg/min.

Largely historical as a shock pressor. SOAP II found no mortality difference overall but significantly more arrhythmic events with dopamine than norepinephrine, and higher mortality in the cardiogenic shock subgroup.⁷ The Surviving Sepsis Campaign recommends against dopamine for septic shock in patients who could receive norepinephrine.⁵ It survives mainly as a chronotropic option in symptomatic bradycardia.

Comparison at a glance

Inotropes and inodilators

A vasopressor raises blood pressure by increasing SVR. An inotrope increases the force of contraction. An inodilator does both inotropy and vasodilation — raising cardiac output while lowering afterload. Getting the distinction right is most of what separates managing distributive shock from managing cardiogenic shock.

Dobutamine: a β₁ agonist that also opens the pipes

Profile: β₁ ≫ β₂, negligible α₁ at usual doses. Range: 2.5–20 mcg/kg/min.

Everything from the β section applies directly: cAMP → PKA → more calcium in the myocyte → stronger, faster, better-relaxing contraction; and cAMP in vascular smooth muscle → vasodilation. So stroke volume rises for two reasons at once — the ventricle squeezes harder and it ejects against less resistance.

That is ideal for the cold-and-wet cardiogenic shock patient with high filling pressures and low output. It is dangerous in a patient whose blood pressure is already marginal, because the β₂ vasodilation can drop MAP below what the coronaries need.

Watch for: tachycardia and arrhythmia, myocardial oxygen demand, and tachyphylaxis — receptor downregulation makes dobutamine progressively less effective over 72 hours or so of continuous infusion.

Milrinone: raising cAMP without touching the receptor

Milrinone is a phosphodiesterase-3 inhibitor. PDE-3 is the enzyme that degrades cAMP. Block it and cAMP accumulates — the same second messenger as β₁ stimulation, produced by preventing its breakdown rather than by increasing its synthesis.

Two consequences follow immediately from that mechanism:

1. It works when β receptors are desensitized or blocked. A patient on chronic beta blockade, or with the downregulated receptors of advanced heart failure, may respond to milrinone when dobutamine does little. This is the single most useful thing to know about it.
2. It vasodilates more than dobutamine — PDE-3 is abundant in vascular smooth muscle, including the pulmonary vasculature. Milrinone is a genuine pulmonary vasodilator, which makes it attractive in right ventricular failure with pulmonary hypertension.

Watch for: hypotension (often the dose-limiting effect), and renal clearance — milrinone's half-life of roughly 2.5 hours in normal renal function stretches substantially in AKI, so the effect, good and bad, persists long after you stop the drip.

Levosimendan and the third mechanism

Levosimendan (available in Europe, not FDA-approved in the US) is a calcium sensitizer: it binds troponin C and stabilizes the calcium-bound conformation, increasing contractile force without increasing cytosolic calcium — theoretically avoiding the arrhythmia and oxygen-demand costs of the cAMP agents. It also opens K_ATP channels, producing vasodilation. Know it as a concept and as the third mechanistic category.

Digoxin: the outlier

Digoxin inhibits the Na⁺/K⁺-ATPase. Intracellular sodium rises, which reduces the gradient driving the Na⁺/Ca²⁺ exchanger, so less calcium leaves the cell and more is stored in the SR — modest positive inotropy by an entirely different route. Its vagotonic AV-nodal slowing is often the more clinically useful effect. Narrow therapeutic index; hypokalemia potentiates toxicity because potassium and digoxin compete for the same binding site on the pump.

The three ways to make a heart squeeze harder

Matching drug to hemodynamic profile

Bedside strategy: sequencing, sparing, and shock stage

The septic shock sequence

The Surviving Sepsis Campaign 2021 gives a clear order, and each step has a mechanistic reason:⁵

1. Norepinephrine first. Strong α₁ with preserved cardiac output and few arrhythmias — the reason it displaced dopamine after SOAP II.⁷
2. Add vasopressin rather than continuing to escalate norepinephrine, typically when norepinephrine reaches roughly 0.25–0.5 mcg/kg/min. A different receptor system, effective in acidosis, and it closes K_ATP channels.^5,10
3. Add epinephrine if MAP remains inadequate on the first two — now you are recruiting β₁ inotropy as well as α₁.
4. Consider corticosteroids for ongoing vasopressor requirement (commonly ≥0.25 mcg/kg/min of norepinephrine or equivalent ≥4 hours in), to restore receptor responsiveness.^5,13
5. Consider angiotensin II for refractory vasoplegia — a third, independent G_q route.¹²

Catecholamine sparing: why "just turn it up" is not free

High-dose catecholamines are not simply neutral chemicals that raise a number. They carry a dose-dependent toxicity that is now well described:⁸

• Arrhythmia — atrial fibrillation and ventricular ectopy from calcium-overloaded myocytes.
• Myocardial injury — catecholamine-mediated myocyte necrosis and stunning; the mechanism shared with takotsubo cardiomyopathy.
• Immunosuppression — β₂ signaling on lymphocytes and macrophages shifts cytokine production and impairs bacterial clearance.
• Metabolic cost — hyperglycemia, hypokalemia, elevated lactate, increased oxygen consumption.
• Regional ischemia — splanchnic and digital hypoperfusion at high α₁ doses.

Hence "multimodal" or "catecholamine-sparing" therapy: reach the MAP target using the lowest total adrenergic exposure, by combining mechanisms.

What MAP target?

The default is MAP ≥65 mmHg in septic shock.⁵

• SEPSISPAM (2014) compared 80–85 versus 65–70 mmHg and found no mortality difference overall; the higher-target group had more atrial fibrillation, but chronically hypertensive patients in the higher-target group needed less renal replacement therapy.¹⁸
• The 65 trial (2020) applied permissive hypotension (target 60–65) in patients over 65 and found no significant difference in 90-day mortality, with less vasopressor exposure.¹⁹

So: 65 is the default; individualize upward for chronic hypertension or evidence of ongoing organ hypoperfusion at 65, and don't chase a number in the absence of perfusion benefit.

SCAI shock stages: a shared language

The SCAI classification (2019, updated 2022) stages cardiogenic shock A through E and is now standard in shock-team communication:²⁰

The 2022 update added a three-axis framework: shock stage, the presence of cardiac arrest, and risk modifiers (age, frailty, comorbidity), because those change prognosis independent of stage.²⁰

Cardiogenic shock: which pressor first?

Norepinephrine, generally. Levy et al. (JACC 2018) randomized epinephrine versus norepinephrine in cardiogenic shock after MI and stopped early for safety: epinephrine caused significantly more refractory shock, higher heart rates and higher lactate for the same MAP effect.¹⁶ SOAP II's cardiogenic subgroup similarly favored norepinephrine over dopamine.⁷ The AHA scientific statement on cardiogenic shock reflects norepinephrine as the usual first vasopressor, with an inotrope added for low output.¹⁵

Weaning

Wean in the reverse order of the toxicity you're trying to avoid, and change one variable at a time. In practice most units wean the titratable catecholamine down first while holding fixed-dose vasopressin, then discontinue vasopressin — but the evidence for wean order is weak and protocols differ; follow yours. Key nursing points: do not abruptly stop vasopressin, since removing a fixed-dose agent can drop MAP abruptly with no titration room; reassess volume status before assuming a failed wean; and document the MAP response to each change so the pattern is visible to the next shift.

When pressors stop working

The drip is at maximum, the MAP is 55, and the resident is asking what you think. Work the mechanism in order — the list below is roughly the order of frequency and of how quickly you can fix it.

1. Is the drug actually reaching the patient?

The most common cause of a pressor "not working" is a delivery problem, not a physiology problem.

• Line issue. Infiltrated peripheral IV, kinked or clamped lumen, disconnected tubing, a line running to a port that isn't open.
• Carrier flow. Vasopressors at low rates in long tubing have a real dead-space transit time. A stopped or slowed carrier fluid can silently interrupt delivery for many minutes; a flush can deliver a bolus.
• Pump programming. Wrong concentration selected, wrong weight entered, mcg/min versus mcg/kg/min confusion, a soft limit overridden.
• Bag exhausted or hung wrong. Check that what is hanging is what the pump thinks is hanging.

2. Is the tank empty?

Vasoconstriction cannot compensate for absent preload indefinitely. Reassess volume status — dynamic measures (stroke volume variation, pulse pressure variation, passive leg raise) rather than a single CVP. Look for occult bleeding, ongoing GI losses, third-spacing, or abdominal compartment syndrome restricting venous return. (The hemodynamics module covers fluid responsiveness in detail.)

3. Is there an obstruction?

Obstructive shock does not respond to pressors because the problem is mechanical:

• Tension pneumothorax — sudden hypotension, unilateral absent breath sounds, tracheal deviation, and in a ventilated patient a rise in peak pressure.
• Cardiac tamponade — muffled heart sounds, JVD, pulsus paradoxus, equalization of diastolic pressures.
• Massive PE — sudden hypoxemia and hypotension with a strained, dilated RV.
• Auto-PEEP / dynamic hyperinflation — a ventilated obstructive patient whose intrathoracic pressure never returns to baseline, throttling venous return. Disconnecting the circuit for several seconds is both diagnostic and therapeutic.

4. Is the pH too low?

Adrenergic receptor affinity falls as pH drops; below roughly 7.15–7.20 catecholamine responsiveness declines meaningfully. Treat the cause of the acidosis (perfusion, ventilation, source control, renal replacement therapy) rather than chasing the number with bicarbonate, which is generally unhelpful and can worsen intracellular acidosis. This is also where vasopressin's pH independence becomes an argument for adding it.

5. Is the endocrine axis failing?

• Critical illness–related corticosteroid insufficiency — reduced receptor expression and unopposed inflammatory vasodilation. The pattern is a rising requirement without a new insult. Hydrocortisone 200 mg/day.^5,13
• Hypothyroidism / myxedema — rare but reversible; suspect with hypothermia, bradycardia, and hyponatremia.
• Severe hypocalcemia — calcium is the final common effector of both pathways in this module. Ionized calcium below roughly 0.9 mmol/L impairs contraction directly; common after massive transfusion (citrate) and in pancreatitis.

6. Is it a receptor problem?

Desensitization, downregulation, or exogenous blockade:

• Beta-blocker or calcium-channel-blocker overdose — the receptor or channel is occupied. This is where high-dose insulin euglycemic therapy, glucagon (which raises cAMP through its own G_s-coupled receptor, bypassing the blocked β receptor) and calcium have specific roles.
• Chronic heart failure — β receptors are already downregulated; milrinone bypasses the receptor entirely.
• Prolonged high-dose catecholamine exposure — GRK/β-arrestin desensitization. Adding a non-adrenergic agent is more effective than adding dose.

7. Is the vasoplegia mechanism itself the problem?

If K_ATP channels are open and iNOS is running, consider the agents that target those specific mechanisms: vasopressin and angiotensin II for the receptor route, methylene blue or hydroxocobalamin for the NO–cGMP route.^4,9

8. Is this the wrong kind of shock?

Reclassify. A patient you have been treating as septic who has a new murmur, a wide pulse pressure and a rising CVP may have papillary muscle rupture. A patient in "cardiogenic shock" with a warm periphery and low SVR may be septic. Point-of-care ultrasound answers most of these questions in minutes.

Escalation beyond drugs

When the pharmacology is exhausted, mechanical support enters: intra-aortic balloon pump, Impella, VA-ECMO for cardiogenic shock (SCAI stages D–E); definitive source control for septic shock. The nursing contribution at that point is recognizing and communicating the trajectory early enough that the shock or ECMO team is called while the patient is still a candidate.

Nursing actions the exam actually tests

The CCRN exam does not ask you to prescribe. It asks you to assess, evaluate the response to an intervention, recognize an emergency, and manage the equipment and the alarms. Here is that content for vasopressors.

Access: central versus peripheral

Vasopressors are ideally given centrally. But the "central line only" rule has softened, and the exam has followed the evidence.

• Extravasation of a vasoconstrictor causes local ischemic necrosis. In a systematic review of extravasation events, the great majority of severe tissue injuries occurred with infusions running longer than several hours and through catheters distal to the antecubital fossa.²¹
• A 2021 systematic review and meta-analysis found the overall rate of extravasation from peripheral vasopressor administration to be low, and tissue injury requiring intervention rarer still — supporting short-term peripheral use while central access is obtained, under a protocol.²²

Practical rules that follow from that evidence: use the most proximal, largest-bore, best-flowing IV available (antecubital or above; avoid hand, wrist and foot); confirm blood return and assess the site frequently — many protocols specify hourly or more often; limit peripheral duration; and escalate to central access.

Titration

• Titrate to the ordered endpoint, not to a comfortable number. The order says "titrate to MAP ≥65"; that is the target, and your documentation should show the MAP at each change.
• Change one thing at a time. If you increase the norepinephrine and open the fluid at the same moment, you have learned nothing about either.
• Allow time between changes. Most catecholamines have half-lives of only a few minutes, but the tubing transit time and the patient's response mean you need a couple of minutes at a new rate before deciding it failed.
• Vasopressin is not titratable at the usual fixed dose; do not treat it as a knob to turn.
• Never bolus or flush a vasopressor line unless specifically ordered — the dead-space volume in the tubing can deliver a large, abrupt dose.
• Anticipate the dead space at start-up. A newly primed line will not deliver drug at the patient for some time at low rates; this is the most common reason a new drip "isn't working."

Monitoring

Recognizing the emergencies

• Abrupt loss of MAP → check the line and the pump before anything else, then think obstruction (tamponade, tension pneumothorax, auto-PEEP, PE).
• New tachyarrhythmia on a catecholamine → check potassium and magnesium, review the dose, tell the provider; a rate-related loss of output can spiral fast.
• Cool, dusky digits or new mottling on a stable dose → regional ischemia; report before it becomes necrosis.
• Rising requirement without a new insult → the pattern that prompts consideration of steroids, source control, or a missed diagnosis.

Evaluating whether the intervention worked

This is the verb the exam uses most. "Worked" is never the MAP alone:

• MAP at or above the ordered target
• Lactate falling (interpreted alongside the epinephrine caveat)
• Urine output improving
• Capillary refill shortening, mottling receding, extremities warming
• Mentation clearing
• Requirement stable or decreasing rather than climbing

Safety systems worth knowing

Smart-pump drug libraries with hard limits; independent double-checks at initiation and at concentration changes; standardized concentrations across the institution; distinct labeling and dedicated lumens; a documented plan for the transport period, when pumps change and lines get disconnected. These are the systems-thinking answers in the Professional Caring domain — the ones about designing the process so the error can't happen, rather than being careful enough to avoid it.